skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Optimizing weight control in diabetes: antidiabetic drug selection

Evidence to Practice

(2742) Views  (1089) Full article downloads

Authors: S Kalra, B Kalra, AG Unnikrishnan, et al

Published Date August 2010 Volume 2010:3 Pages 297 - 299
DOI: http://dx.doi.org/10.2147/DMSO.S11941

S Kalra1, B Kalra1, AG Unnikrishnan2, N Agrawal3, S Kumar4

1Bharti Hospital, Karnal; 2Amrita Institute of Medical Science, Kochi; 3Medical College, Gwalior; 4Excel Life Sciences, Noida, India

Date of preparation: 18th August 2010

Conflict of interest: SK has received speaker fees from Novo Nordisk, sanofi-aventis, MSD, Eli Lilly, BMS, and AstraZeneca.

Clinical question: Which antidiabetic drugs provide optimal weight control in patients with type 2 diabetes?

Results: Metformin reduces weight gain, and may cause weight loss, when given alone or in combination with other drugs. Pioglitazone and rosiglitazone use is associated with weight gain. Use of the glucagon-like peptide-1 (GLP-1) analogs, liraglutide and exenatide, is associated with weight loss. Dipeptidyl peptidase-4 (DPP-4) inhibitors are considered weight-neutral. Results with insulin therapy are conflicting. Insulin detemir provides weight control along with glycemic control.

Implementation:

• Weight gain is considered an inevitable part of good glycemic control using conventional modalities of treatment such as sulfonylureas.

• Use of metformin, weight-sparing insulin analogs such as insulin detemir, and liraglutide, should be encouraged as monotherapy, or in combination with other drugs.

Keywords: weight control, diabetes






 

Other articles by Dr S Kalra



Readers of this article also read:

Evidence-based decision-making within the context of globalization: A “Why–What–How” for leaders and managers of health care organizations
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Potential renovascular hypertension, space missions, and the role of magnesium
Ego mechanisms of defense are associated with patients’ preference of treatment modality independent of psychological distress in end-stage renal disease
Can a gentamicin-specific chart reduce neonatal medication errors?
Nephroprotective action of glycosaminoglycans: why the pharmacological properties of sulodexide might be reconsidered
Dashboards in neonatology
Retinal nerve fiber layer evaluation in multiple sclerosis with spectral domain optical coherence tomography
Everolimus-eluting stents: update on current clinical studies
Differential pharmacology and benefit/risk of azilsartan compared to other sartans
  • Testimonials

    "You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio